Yahoo Finance's On the Move panel discuss the latest headline making news stories.
- Yahoo Finance Video
Airbnb will confidentially file for an IPO this month, according to The Wall Street Journal. Yahoo Finance's On The Move panel discusses.
- Yahoo Finance Video
Yahoo Finance’s On The Move panel discuss what's moving the world of finance.
- Yahoo Finance Video
According to a report by the Wall Street Journal, Airbnb has plans to confidentially file for a public listing with the SEC by the end of the year. Yahoo Finance’s The Final Round discuss the report and what impact it could have on the company.
- Motley Fool
It's been a brutal year for the travel industry, but Airbnb's results might be picking back up.
- Yahoo Finance Video
Yahoo Finance’s Anjalee Khemlani joins the On the Move panel to discuss Vladimir Putin’s claims that Russia has a COVID-19 vaccine.
- Yahoo Finance Video
Ariel Investments Vice Chairman Charlie Bobrinskoy joins the On the Move panel to discuss what Joe Biden's vice presidential pick Kamala Harris means for Wall Street.
According to The Wall Street Journal, Airbnb could file confidentially to go public as early as this month. The same report states that Airbnb could follow that filing with an IPO before year's end. Morgan Stanley and Goldman are helping the former startup with its IPO process, the Journal writes.
- Yahoo Finance Video
Walmart will partner with Instacart to offer same-day delivery in U.S. markets. Yahoo Finance’s On The Move panel share the details.
Airbnb is preparing to potentially go public before the end of the year, the report said, citing sources familiar with the matter. Reuters had reported in October that Airbnb was close to hiring Morgan Stanley and Goldman Sachs Group Inc as joint lead advisers on its planned stock market flotation.
Unfortunately, not all jobs are financially worth the education cost it takes to obtain them.
- Yahoo Finance Video
Tesla shares soar after the automaker set a five-for-one stock split. Oppenheimer Senior Research Analyst Colin Rusch joins Yahoo Finance’s On The Move panel to discuss.
- Yahoo Finance Video
Stocks on the Move: Canada Goose down on decline in traffic due to virus; NIO trading lower on Q2 earnings miss
Yahoo Finance's On the Move panel break down today's 'Stocks on the Move': Canada Goose and NIO.
BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- CBS News Videos
Here's a look at the top stories making headlines on the "CBS Evening News with Norah O'Donnell."
- CBS News Videos
Here's a look at the top stories making headlines on the "CBS Evening News with Norah O'Donnell."
- Yahoo Finance Video
Yahoo Finance's Jared Blikre breaks down some of the features of the Yahoo Finance Premium package. Not a subscriber? Start your free trial to join future webinars live!
Home Depot (HD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- WTVD – Raleigh/Durham
An ongoing conversation about race, police brutality and the current demonstrations made its way to Fayetteville on Tuesday for an online, virtual panel.
- Yahoo Finance Video
We’re giving minorities in New York more reasons to be optimistic about the future: Montefiore CEO on hiring initiative
Montefiore CEO Dr. Philip Ozuah joins Yahoo Finance’s On The Move panel to discuss why companies pledged to hire minority New Yorkers amid the pandemic.
These options truly make good on their claims.Originally Appeared on Glamour
- Meredith Videos
Jeff Foxworthy talks his new show 'What's It Worth?' airing Tuesdays at 9 p.m. ET on A&E
Salesforce (NYSE: CRM) introduced a new feedback management suite earlier this month that the company said includes custom survey design and enterprise-level tracking tools.This feature is in the same space that Qualtrics has dominated in recent years. With Qualtrics announcing a plan to go public soon, Salesforce's suite could have an impact on the company's long-term growth.Qualtrics IPO Plans: Qualtrics was weeks away from going public when it was bought for $8 billion by SAP SE (NYSE: SAP) in 2018. Now, the German company has announced their desire to take Qualtrics public in the United States.Qualtrics has reported over 2 million users worldwide, with 75% of Fortune 100 Companies using its experience management and survey platform.The company is built around the user experience and management space that Salesforce is now entering.Salesforce's New Product: Salesforce's feedback management system allows for customized survey design that can be added to its sales or service cloud.While Salesforce's newest product is not as far along as the Qualtrics suite of products, Salesforce did also announce "Einstein" capabilities that will allow for automated analysis of the collected data.In July, Salesforce overtook Oracle (NYSE: ORCL)'s market cap, at $180 billion vs. $174 billion. The CRM Market: Salesforce has fought for market share in the customer relationship management space and now holds 18.4% of CRM market share, while Qualtrics owner SAP SE has 5.3% of the CRM market share.Salesforce can now be a one-stop survey and CRM provider for clients -- and a competitor to Qualtrics.Qualtrics has premade Salesforce integration in its products, so it will be interesting to see if that shared API partnership continues.Photo courtesy of Salesforce. See more from Benzinga * Why StockX Activity Is Up 50% Year-Over-Year: A Rally In The Stock Market Of Things(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Yahoo Finance Video
Climate app Klima launched its new beta app on Wednesday, with help from a $5.8 million seed round. Klima CEO Markus Gilles joins Yahoo Finance’s on The move panel to weigh in on the company’s outlook.
* Strong double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts(1) (non-GAAP) * Company introduces 2020 guidance: Adjusted Cash Receipts expected to be $1,720 to $1,760 million * $1.7 billion of new acquisitions announced in 2020 NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2020 and introduced full-year 2020 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).“2020 has been a landmark year for Royalty Pharma,” said Pablo Legorreta, Founder and Chief Executive Officer. “We achieved a major milestone with our initial public offering which raised $1.9 billion in capital to drive future growth. We have also announced approximately $1.7 billion in new transactions this year which reflects our unique position in the life sciences ecosystem. At the same time, we continue to see strong performance in our business. In the second quarter, Net cash provided by operating activities grew 33% and Adjusted Cash Receipts increased 24%, supporting Adjusted Cash Flow growth of nearly 50%. Additionally, the FDA approvals of Evrysdi, Trodelvy, Nurtec ODT and Tazverik during 2020 have expanded our portfolio of long duration assets and provide further diversification. As the biopharma industry experiences an extraordinary period of scientific advancement, Royalty Pharma expects to play a key role in funding innovation and to deliver attractive and sustained long-term growth for its shareholders,” Pablo Legorreta added.GAAP financial results demonstrate strong operating cash flow generation and revenue growth * Cash provided by operating activities increased to $489 million compared with $368 million on a pro forma basis in the same period of 2019 primarily driven by higher royalty receipts. * Cash used in investing activities of $249 million largely reflected two royalty acquisitions. * Cash provided by financing activities of $1,579 million was driven by the receipt of IPO proceeds. * Total income and other revenues increased 12% driven by growth from the cystic fibrosis franchise and Imbruvica.Non-GAAP financial results driven by double-digit increases across multiple products in the portfolio * Adjusted Cash Receipts(1) increased 24% on a pro forma basis led by the cystic fibrosis franchise and Imbruvica. * Adjusted Cash Flow(2) grew 47% on a pro forma basis to $369 million, enhanced by lower financing expenses.Portfolio continues to expand with new approvals and royalty acquisitions * Recent royalty acquisitions include Prevymis (cytomegalovirus infection), IDHIFA (acute myeloid leukemia) and Evrysdi (spinal muscular atrophy) as well as an expanded funding agreement with Biohaven for Nurtec ODT and zavegepant, resulting in approximately $1.7 billion in announced transactions this year. * FDA approvals granted for Trodelvy (triple-negative breast cancer), Tazverik (follicular lymphoma) and Evrysdi. (unaudited) For the three months ended June 30 ($ and shares in millions)2020 2019(3) Pro FormaChange Net cash provided by operating activities (GAAP)489 36833% Net cash used in investing activities (GAAP)(249) n/an/a Net cash provided by financing activities (GAAP)1,579 n/an/a Total income and other revenues (GAAP)511 45812% Adjusted Cash Receipts (1) (non-GAAP)462 37324% Adjusted Cash Flow (2) (non-GAAP)369 25047% Fully diluted shares outstanding as of June 30, 2020 607 n/an/a Second quarter financial results (unaudited) For the three months ended June 30 ($ in millions) 2020 2019 Pro forma(3)Change Net cash provided by Operating activities (GAAP)489 368 33% Royalty Receipts:Marketer:Therapeutic Area: Cystic fibrosis franchiseVertexRare diseases136 86 59% TysabriBiogenNeurology93 82 13% ImbruvicaAbbVie/Johnson & JohnsonCancer82 66 23% HIV franchiseGilead, othersInfectious disease65 52 24% Januvia, Janumet, other DPP-IVsMerck & Co., othersDiabetes35 41 (15)% XtandiPfizer, AstellasCancer34 27 26% PromactaNovartisHematology27 19 38% Farxiga/OnglyzaAstraZenecaDiabetes8 - n/a PrevymisMerck & Co.Infectious diseases6 - n/a CrysvitaUltragenyx, Kyowa KirinRare diseases3 - n/a ErleadaJohnson & JohnsonCancer2 - n/a EmgalityEli LillyNeurology2 - n/a LyricaPfizerNeurology6 35 (82)% LetairisGileadCardiology8 22 (66)% Other Products (4) 79 55 43% Total Royalty Receipts 585 486 20% Distributions to non-controlling interests(123) (114) 8% Adjusted Cash Receipts (non-GAAP) (1)462 373 24% Amounts shown in the table may not add due to rounding The difference between Pro forma and reported results for Total Royalty Receipts relate to the treatment of Legacy SLP interest in “Other Products.” Net cash provided by operating activities (GAAP) was $489 million in the three months ended June 30, 2020 compared to $368 million on a pro forma basis in the same period of the prior year. The primary driver was an increase in cash collections from financial royalty assets, primarily from the cystic fibrosis franchise and Imbruvica, as discussed below. In the second quarter of 2020, payments for interest were lower under the refinanced credit facilities while Development-stage funding payments reduced as a result of the completion of the funding arrangement with Pfizer in 2019.Total Royalty Receipts were $585 million, an increase of 20% in the second quarter of 2020 compared to the same period of 2019 on a pro forma basis. This was largely attributable to the performance of the cystic fibrosis franchise, Imbruvica and the addition of new royalties, partially offset by a decrease in royalties for Lyrica and Letairis resulting from losses of exclusivity.Drivers of royalty receipts in the quarter are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts lag product performance by one calendar quarter). * Cystic fibrosis franchise – Royalty receipts from Vertex’s cystic fibrosis franchise, which includes Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta, all approved for patients with certain mutations causing cystic fibrosis, were $136 million in the second quarter of 2020, an increase of 59% compared to the same period of 2019 on a pro forma basis, primarily driven by the highly successful launch of Trikafta in the U.S. * Tysabri – Royalty receipts from Tysabri, which is marketed by Biogen for the treatment of multiple sclerosis, were $93 million in the second quarter of 2020, an increase of 13% compared to the same period of 2019. * Imbruvica – Royalty receipts from Imbruvica, which is marketed by AbbVie and Johnson & Johnson for the treatment of blood cancers and chronic graft versus host disease, were $82 million in the second quarter of 2020, an increase of 23% compared to the same period of 2019. * HIV franchise – Royalty receipts from the HIV franchise, which is based on products marketed by Gilead that contain emtricitabine, including Biktarvy, Genvoya and Truvada, among others, were $65 million in the second quarter of 2020, an increase of 24% compared to the same period of 2019. * Januvia, Janumet, Other DPP-IVs – Royalty receipts from the DPP-IVs for type 2 diabetes, which include Januvia and Janumet, both marketed by Merck & Co., were $35 million in the second quarter of 2020, a decrease of 15% compared to the same period of 2019, reflecting continued pricing pressure in the U.S. * Xtandi – Royalty receipts from Xtandi, which is marketed by Pfizer and Astellas for the treatment of prostate cancer, were $34 million in the second quarter of 2020, an increase of 26% compared to the same period of 2019, driven by demand across various prostate cancer indications. * Promacta – Royalty receipts from Promacta, which is marketed by Novartis for the treatment of chronic immune thrombocytopenia purpura (ITP) and aplastic anemia, were $27 million in the second quarter of 2020, an increase of 38% compared to the same period of 2019. Global growth was driven by increased use in ITP and further uptake as first-line treatment for severe aplastic anemia in the US. Royalty Pharma acquired the Promacta royalty in March 2019.Distributions to non-controlling interests were $123 million in the second quarter of 2020, an increase of 8% compared to the same period of 2019 on a pro forma basis, which reduces royalty receipts to arrive at Adjusted Cash Receipts.Adjusted Cash Receipts (non-GAAP) (1) were $462 million in the second quarter of 2020, an increase of 24% compared to the same period of 2019 on a pro forma basis, primarily as a result of performance of the cystic fibrosis franchise, Imbruvica and Other Products. This was partially offset by the increase in distributions to non-controlling interests as discussed above, as well as the decrease in royalty receipts from Lyrica and Letairis resulting from their losses of exclusivity.Adjusted EBITDA (5) is a non-GAAP measure used by Royalty Pharma which comprises Adjusted Cash Receipts less payments for operating costs and professional services. In the second quarter of 2020, Adjusted EBITDA was $418 million, a 25% increase compared to Adjusted EBITDA of $333 million on a pro forma basis in 2019: * The increase was largely attributable to the 24% growth in Adjusted Cash Receipts. * Payments for operating and professional costs amounted to $44 million in the quarter (representing 9.6% of Adjusted Cash Receipts), versus $39 million (10.6% of Adjusted Cash Receipts) in the second quarter of 2019 on a pro forma basis.Adjusted Cash Flow (2) is a non-GAAP measure which is comprised of Adjusted EBITDA less R&D funding, Net interest paid and miscellaneous other items relating to swap arrangements, investment in non-consolidated affiliates and contributions from non-controlling interests. In the second quarter of 2020, Adjusted Cash Flow was $369 million, a 47% increase compared to Adjusted Cash Flow of $250 million for the same period of 2019 on a pro forma basis. The increase was primarily driven by the growth in Adjusted Cash Receipts as well as lower Net interest paid and Development-stage funding payments. Items in the period included: * Development-stage funding payments of $6 million in the second quarter was significantly lower than the $21 million in the same period in 2019, as ongoing R&D programs (primarily related to the Phase 3 adjuvant studies of Ibrance) reached completion at the end of 2019. * Net interest paid of $31 million was lower than the $57 million paid in the same period of 2019 on a pro forma basis due to the impact of debt refinancing and a reduction in interest rates. * Investment in non-consolidated affiliates was $16 million, up from $10 million in the second quarter of 2019. * Contributions from non-controlling interest-R&D were $4 million in in the second quarter, as compared with $6 million in the year-ago period on a pro forma basis.A more comprehensive discussion of the non-GAAP measures utilized by Royalty Pharma to manage its business can be found in the section of this earnings release entitled ‘Use of Non-GAAP Measures’.Recent Events Related to our Portfolio * Cystic fibrosis franchise: In June 2020, Vertex announced that EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the triple combination therapy Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination with Kalydeco in people ages 12 and older with cystic fibrosis with the most common genotype. If granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease, and people 12 years of age and older who have two F508del mutations also will be eligible for the new triple combination regimen. * Tazverik (tazemetostat): In June 2020, Epizyme, Inc. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of the supplemental New Drug Application (sNDA) for Tazverik for two distinct follicular lymphoma (FL) indications, including adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies and adult patients with relapsed or refractory FL who have no satisfactory alternative treatment options. * Ibrance (palbociclib): In May 2020, Pfizer reported that the independent data monitoring committee for the PALLAS trial had concluded after the recent interim analysis that the PALLAS trial is “unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival.” If Pfizer’s PENELOPE-B trial is successful, Royalty Pharma will be entitled to receive approval-based fixed milestone payments of $250 million. * Trodelvy (sacituzumab govitecan-hziy): In April 2020, Immunomedics announced that the FDA granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for the treatment of patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first antibody-drug conjugate (ADC) approved by the FDA specifically for TNBC. Summary of Recent Royalty Acquisition Activity * Nurtec ODT (rimegepant) and zavegepant: In August 2020, Royalty Pharma announced an expanded agreement with Biohaven Pharmaceuticals for up to $450 million to fund the development of zavegepant and the commercialization of Nurtec ODT. To support the zavegepant Phase 3 program, Biohaven will receive a $150 million upfront payment and an additional $100 million payment upon the start of the oral zavegepant phase 3 program. Royalty Pharma will receive a royalty of 0.4% on Nurtec ODT, a royalty of up to 3% on zavegepant and success-based milestone payments based on zavegepant regulatory approvals. Royalty Pharma will also provide further support for the ongoing launch of Nurtec ODT through the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200 million payable between 2021 and 2024. * Evrysdi (risdiplam): In July 2020, Royalty Pharma acquired a royalty on Evrysdi, a development-stage product candidate for the treatment of Types 1, 2 and 3 spinal muscular atrophy (SMA), from PTC Therapeutics, Inc. in exchange for an upfront payment of $650 million. Evrysdi was subsequently approved by FDA on August 7, 2020, representing the first at home, oral treatment approved for infants, children and adults with all SMA types. * IDHIFA (enasidenib): In June 2020, Royalty Pharma acquired a royalty on IDHIFA, an approved product for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation, from Agios Pharmaceuticals, Inc. in exchange for an upfront payment of $255 million. * Prevymis (letermovir): In April 2020, Royalty Pharma acquired a royalty on Prevymis, an approved product to prevent cytomegalovirus (CMV) infection in stem cell transplants, from AiCuris Anti-infective Cures GmbH in exchange for an upfront payment of $220 million.Liquidity and Capital Resources * At June 30, 2020, Royalty Pharma had cash, cash equivalents and marketable securities in the amount of $2,787 million and $5,912 million of long-term debt, inclusive of unamortized issuance cost and discount of $34 million. * Royalty Pharma’s initial public offering (IPO) was completed on June 18, 2020, whereby the company issued 89.3 million shares of Class A ordinary shares at a price to the public of $28 per share, of which 71.7 million and 17.7 million shares were offered by the company and selling shareholders, respectively. The number of Class A ordinary shares issued at closing included the exercise in full of the underwriters’ option to purchase 11.7 million additional Class A ordinary shares from the company. The company received net proceeds of approximately $1.9 billion from the IPO. The Class A ordinary shares began trading on the Nasdaq Global Select Market under the ticker symbol “RPRX” on June 16, 2020. * Following the IPO, Royalty Pharma has 607.1 million fully diluted shares outstanding.2020 Financial OutlookRoyalty Pharma has provided guidance for 2020 as follows: Provided August 12, 2020 Adjusted Cash Receipts (non-GAAP) excluding new transactions announced after the date of this release$1,720 million to $1,760 million The company also expects that Payments for operating and professional costs will be approximately 10% of Adjusted Cash Receipts in 2020.Royalty Pharma today provides this guidance based on its first-half performance and on its most up-to-date view on the company’s prospects. This guidance assumes no major unforeseen adverse events and excludes the contributions from transactions announced subsequent to the date of this press release. Furthermore, Royalty Pharma reserves the right to amend its guidance in the event it engages in new royalty transactions which have a material near-term financial impact on the company.Royalty Pharma has not reconciled its non-GAAP 2020 guidance to the most directly comparable GAAP measure, Net cash provided by operating activities, at this time due to the inherent difficulty in accurately forecasting and quantifying certain amounts that are necessary for such reconciliation, including, primarily, Payments for operating and professional costs, Distributions from non-consolidated affiliates, and Interest received. We are not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to project net cash provided by operating activities at this time.Earnings Conference CallRoyalty Pharma will host a conference call and simultaneous webcast to discuss this earnings release today at 8:00 AM, Eastern Time. A link to the webcast may be accessed from the 'Investors' page of Royalty Pharma’s website or at https://edge.media-server.com/mmc/p/2ujdenpf. Please allow at least five minutes for registering and accessing the presentation. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. To ask a question during the live broadcast or listen without Internet access, please dial in at least 15 minutes in advance to ensure a timely connection to the call. The dial in number to join the call is (833) 519-1253 from within the United States; the number for international callers is + 1 (914) 800-3826. Enter the passcode 6299563 when prompted.About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. For more information, visit www.royaltypharma.com.Forward-Looking Statements The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.For further information, please reference our reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.Use of Non-GAAP MeasuresAdjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to our GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because our operating performance is a function of our liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. We caution readers that amounts presented in accordance with our definitions of Adjusted Cash Receipts, Adjusted EBITDA, and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures we use in the same manner. We compensate for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being Net cash provided by operating activities.We believe that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about our operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising our operating results. Management strongly believes that our significant operating cash flow is one of the attributes that attracts potential investors to our business.In addition, we believe that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses the performance of the company, including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Both measures are an indication of the strength of the company and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee, and investors evaluate the company’s ability to generate liquidity from operating activities.Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing our liquidity and is a key component of certain material covenants contained within the company’s Credit Agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the credit agreement could result in our lenders requiring the company to immediately repay all amounts borrowed. If we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of our liquidity.Management uses Adjusted Cash Flow to evaluate its ability to generate cash and performance of the business and to evaluate the company’s performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company’s metric may not be directly comparable to another’s. We believe that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors, and other interested parties to evaluate companies in our industry.The non-GAAP financial measures used in this earnings release have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of our results as reported under GAAP. The company has provided a reconciliation of each non-GAAP financial measure, except for its non-GAAP outlook to the most directly comparable GAAP financial measure, in each case being Net cash provided by operating activities at Table 5. Royalty Pharma plc Condensed Consolidated Income Statement (unaudited) Table 1 (As reported) For the three months ended June 30 ($ in millions)2020 2019 Total income and revenues Income from financial royalty assets474 417 Revenue from intangible royalty assets33 35 Other royalty income3 5 Total income and other revenues511 458 Operating expenses Research and development funding expense6 21 Provision for changes in expected cash flows from financial royalty assets47 72 Amortization of intangible assets6 6 General and administrative expenses43 30 Total operating expenses, net102 130 Operating income409 328 Other (income)/expense Equity in (earnings)/loss of non-consolidated affiliates(29) 8 Interest expense34 69 Other (income)/expense(198) 72 Total other (income)/expense, net(193) 149 Consolidated net income before tax602 179 Income tax expense- - Consolidated net income602 179 Less: Net income attributable to non-controlling interest(160) (27) Net income attributable to controlling interest442 152 Amounts may not add due to rounding. Royalty Pharma plc Selected Balance Sheet Data Table 2 (unaudited) ($ in millions)As of June 30, 2020As of December 31, 2019 Cash and cash equivalents2,443284 Marketable securities34457 Total assets15,68612,450 Current portion of long-term debt182282 Long-term debt, excluding current portion5,7305,956 Total liabilities6,2916,308 Total shareholders’ equity9,3956,141 Royalty Pharma plc Condensed Consolidated Statements of Cash Flows (unaudited) Table 3 (As reported)(As reported) ($ in millions)For the three months ended June 30For the six months ended June 30 2020 2019 2020 2019 Cash flows from operating activities: Cash collections from financial royalty assets515 427 1,004 895 Cash collections from intangible royalty assets35 41 70 74 Other royalty cash collections8 7 9 21 Interest received1 4 4 14 Swap collateral received- - 45 0.4 Swap collateral posted- (26) - (27) Swap termination payments- - (35) - Distributions from non-consolidated affiliates12 - 32 14 Development-stage funding payments—ongoing(6) (21) (13) (44) Payments for operating and professional costs(44) (29) (70) (47) Interest paid(32) (66) (83) (130) Net cash provided by operating activities489 337 960 770 Cash flows from investing activities: Distributions from non-consolidated affiliates15 - 15 - Purchases of available for sale debt securities- (125) - (125) Purchase of equity securities- - (50) - Proceeds from available for sale debt securities- - - 150 Purchase of marketable securities- - (637) - Proceeds from sales and maturities of marketable securities227 - 354 - Investments in non-consolidated affiliates(16) (10) (29) (19) Acquisitions of financial royalty assets(475) (23) (575) (1,232) Milestone payments- - - (250) Net cash used in investing activities(249) (158) (922) (1,476) Cash flows from financing activities: Distributions to shareholders/unitholders(144) (198) (285) (396) Distributions to non-controlling interest(123) (36) (285) (78) Distributions to non-controlling interest – other(28) - (28) - Contributions from non-controlling interest- acquisitions- - 17 - Contributions from non-controlling interest- R&D4 - 5 - Contributions from non-controlling interest- other- - 13 - Scheduled repayments of long-term debt(47) (74) (94) (147) Repayments of long-term debt- - (5,170) - Proceeds from issuance of long-term debt- - 6,040 - Debt issuance costs and other(1) (2) (9) - Purchase of treasury interests- - - (4) Proceeds from issuance of ordinary shares upon initial public offering, net of offering costs1,918 - 1,918 - Net cash provided by / (used in) financing activities1,579 (310) 2,122 (625) Net change in cash and cash equivalents1,819 (132) 2,160 (1,331) Cash and cash equivalents, beginning of period624 (916) 284 1,924 Cash and cash equivalents, end of period2,443 (1,047) 2,443 593 Amounts may not add due to rounding.Royalty Pharma plc Non-GAAP Financial Measures (unaudited) Table 4($ in millions)For the three months ended June 30 2020 2019 Pro Forma(3)change Net cash provided by Operating activities (GAAP)489 368 33% Products: Cystic fibrosis franchise136 86 59% Tysabri93 82 13% Imbruvica82 66 23% HIV franchise65 52 24% Januvia, Janumet, Other DPP-IVs35 41 (15)% Xtandi34 27 26% Promacta27 19 38% Farxiga/Onglyza8 - n/a Prevymis6 - n/a Crysvita3 - n/a Erleada2 - n/a Emgality2 - n/a Lyrica6 35 (82)% Letairis8 22 (66)% Other Products (4)79 55 43% Total Royalty Receipts585 486 20% Distributions to non-controlling interest (123) (114) 8 Adjusted Cash Receipts (non-GAAP) (1) 462 373 24% Payments for operating and professional costs(44) (39) 12% Adjusted EBITDA (non-GAAP) (5)418 333 25% Development-stage funding payments – ongoing(6) (21) (73)% Interest paid, net(31) (57) (46)% Investment in non-consolidated affiliates(16) (10) 64% Contributions from non-controlling interest- R&D4 6 (30) Adjusted Cash Flow (non-GAAP) (2)369 250 47% Amounts may not add due to rounding. Royalty Pharma plc GAAP to Non-GAAP Reconciliation (unaudited) Table 5 For the three months ended June 30 ($ in millions)2020 2019 Pro Forma(3) Net cash provided by operating activities (GAAP)489 368 Adjustments: Distributions from non-consolidated affiliates - investing(6)15 - Interest paid, net (6)31 57 Development-stage funding payments – ongoing (7)6 21 Payments for operating and professional costs44 39 Swap termination payments- - Distributions to non-controlling interests (6)(123) (114) Adjusted Cash Receipts (non-GAAP) (1)462 373 Net cash provided by operating activities (GAAP)489 368 Adjustments: Distributions from non-consolidated affiliates - investing(6)15 - Interest paid, net (6)31 57 Development-stage funding payments – ongoing (7)6 21 Swap termination payments- - Distributions to non-controlling interests (6)(123) (114) Swap collateral posted or (received), net (6)- - Adjusted EBITDA (non-GAAP) (5)418 333 Net cash provided by operating activities (GAAP)489 368 Adjustments: Distributions from non-consolidated affiliates - investing(6)15 - Contribution from non-controlling interest- R&D (6)4 6 Distributions to non-controlling interests (6)(123) (114) Investment in non-consolidated affiliates (6) (8)(16) (10) Adjusted Cash Flow (non-GAAP) (2)369 250 Amounts may not add due to rounding. Notes (1) Adjusted Cash Receipts is a measure calculated with inputs directly from the Statement of Cash Flows and includes (1) royalty receipts: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) Other royalty cash collections, (iii) Distributions from non-consolidated affiliates, plus (2) Proceeds from available for sale debt securities (Tecfidera milestone payments), and less (3) Distributions to non-controlling interest, which represents distributions to our historical non-controlling interest attributable to a de minimis interest in RPCT held by certain legacy investors and to a new non-controlling interest that was created as a result of the Exchange Offer Transactions in February 2020 related to the Legacy Investors Partnerships' ownership of approximately 18% in Old RPI. See our Prospectus for additional discussion. See GAAP to Non-GAAP reconciliation at Table 5. (2) Adjusted Cash Flow is defined as Adjusted EBITDA less (1) Development-stage funding payments – ongoing, (2) Interest paid, net, (3) Swap collateral (posted) or received, net, (4) Swap termination payments, and (5) Investment in non-consolidated affiliates, and plus (1) Contributions from non-controlling interest- R&D, all directly reconcilable to the Statement of Cash Flows. See GAAP to Non-GAAP reconciliation at Table 5.(3) To aid in comparability, three months ended June 30, 2019 figures are presented on an unaudited pro forma basis, which adjusts certain cash flow line items as if Royalty Pharma’s Reorganization Transactions (as described in the Company’s final prospectus filed with the SEC on June 17, 2020 (‘Prospectus’)) and its initial public offering (IPO) had taken place on January 1, 2019. The most significant difference between the pro forma and reported figures is the new non-controlling interest that resulted from the Reorganization Transactions. A new contractual non-controlling interest arose in the Reorganization transaction that results in a higher distribution to non-controlling interests on a pro forma basis as compared to prior historical periods. Less material differences also arise in the Royalty Receipts line for ‘Other Products’ as well as Payments for operating and professional costs, and interest paid, net. (4) Other Products include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as Distributions received from nonconsolidated affiliates on the Statement of Cash Flows), Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Prezista, Priligy, Rotateq, Savella, Soliqua and Thalomid. Other Products also include contributions from the Legacy SLP Interest and a distribution from Avillion in respect of the Merck KGaA Asset, for which development ceased in 2020, and for which the receipt is presented as Distributions received from non-consolidated affiliates in both the operating and investing section of the Statement of Cash Flows. (5) Adjusted EBITDA is important to our lenders and is defined under the credit agreement Adjusted Cash Receipts less payments for operating and professional costs. Operating and professional costs are comprised of Payments for operating costs and professional services and Payments for rebates from the Statement of Cash Flows. See GAAP to Non-GAAP reconciliation at Table 5.(6) The table below shows the line item for each adjustment and the direct location for such line item on the Statement of Cash Flows. Reconciling adjustmentStatement of Cash Flows classification Investments in non-consolidated affiliatesInvesting activities Distributions to non-controlling interestsFinancing activities Interest paid, netOperating activities (Interest paid less Interest received) Contributions from non-controlling interest- R&DFinancing activities Distributions from non-consolidated affiliates - investingInvesting activities (7) Our lenders consider all payments made to support R&D activities for products undergoing late-stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. All development-stage funding payments - ongoing and upfront - run through R&D funding expense in net income and are added back in aggregate to Net cash provided by operating activities to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for R&D funding payments while Adjusted Cash Flow only reflects the add-back for the upfront portion of development-stage funding payments due to the fact that development-stage funding payments – ongoing are considered an ongoing business expense.(8) We consider all payments to fund our operating joint ventures that are performing research and development activities for products undergoing late stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by our equity method investees, the Avillion entities, are added back to Adjusted Cash Flow.Royalty Pharma Investor Relations and Communications+1 (212) 883-2295 email@example.com
- Yahoo Finance Video
Yahoo Finance’s Denitsa Tsekova joins Kristin Myers to discuss new analysis which reveals 1 in 3 Americans out of a job will not be helped by President Trump's latest executive orders.
FuboTV has filed for an IPO with the Securities & Exchange Commission -- as CEO David Gandler promised back when the live streaming platform merged with Facebank Group in April to “uplist” the securities to a major stock exchange. Fubo declined to comment beyond the initial public offering registration submitted to the SEC for approval. […]
- Business Insider
Airbnb will confidentially file its IPO paperwork later this month, The Wall Street Journal reported.
- Yahoo Finance Video
Brightmark CEO Bob Powell joins Yahoo Finance's On The Move panel to break down how his company is reimagining waste-to-energy solutions amid the coronavirus pandemic.
Adtalem (ATGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Advance Auto Parts (AAP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Yahoo Finance Video
Retirees are having to 'take more risks than our parents' generation' in current investing climate: Neuberger Berman MD
Holly Newman Kroft, Neuberger Berman Managing Director joins the On the Move panel to discuss the markets response to COVID-19 and how investors should guide their clients through this volatile period.
Agilent (A) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Yahoo Sports Videos
Yahoo Sports' Scott Pianowski is joined by TJ Hernandez from 4for4 Fantasy Football and they discuss what we can expect in year two for Jaguars QB Gardner Minshew. Subscribe to the Yahoo Fantasy Football Forecast on Apple Podcasts, Spotify or wherever you get your podcasts.
- Yahoo Finance Video
Yahoo Finance's Jared Blikre joins Myles Udland to break down the day's price action in stocks as well as a long in Merck (MRK), a Yahoo Finance Premium Investment Idea. Not a subscriber? Start your free trial to join future webinars live!
Shares in Lemonade (LMND) dropped 5% in Tuesday’s after-hours trading after the digital insurance company reported its inaugural earnings following the July 2 IPO. 2Q adjusted gross profit was modestly ahead of Street estimates, with KPIs beating substantially.Specifically, Q2 GAAP EPS of -$1.77 beat Street forecasts by $0.41 while revenue of $29.9M surged 116.7% year-over-year, and topped consensus expectations by $0.59M.Gross Earned Premium came in up 121% year-over-year and 4% above Street estimates, vs. 1Q’s 143%. And 2Q adjusted gross profit rose 203% year-over-year, yielding a 20% ratio of adjusted gross profit to gross earned premium.IFP, defined as the aggregate annualized premium for customers as of the period end date, soared 115% to $155.1M compared to the same quarter last year, primarily due to an 84% rise in the number of customers, as well as a 17% increase in premium per customer. Indeed total customer count was up 84% at 814,160 vs 2Q 2019.However, looking forward, LMND is guiding for Q3 revenue of $14M-$15M, falling short of the $15.2M consensus and $29.9M revenue delivered during the second quarter. That’s alongside revenue for the full year of $86M-$88M- again coming slightly below the $88.9M expected by consensus.“Q3 is, historically, a moving season, and has typically been our strongest growth quarter as many people move in time for the new school year. The pandemic has put school openings in question – and we don’t know how this may change the migratory patterns of Americans” the company commented. (See LMND stock analysis on TipRanks).Shares in Lemonade are trading down 9% since the IPO and the Street has a cautious Hold consensus on the stock’s outlook. That’s with an average analyst price target of $81, indicating upside potential of 29%.“We see shares as fully valued at this level and encourage investors to wait for a better entry point” explains Oppenheimer’s Jason Helfstein, adding that LMND shares currently trade at 41x 2022E EV/GP, a 258% premium to peers, though LMND is growing ’19-‘22E gross profit 268% faster.Related News: Pfenex Pops 59% On Ligand $513M Buy-Out Deal; Analyst Sees 93% Upside MGM Spikes 14% As IAC Makes $1B Investment Amid Online Gambling Bet American Express’ Net Income Sinks 85% Due To Travel Spending Squeeze More recent articles from Smarter Analyst: * Stifel Lifts Lumentum’s PT After 4Q Earnings Beat Estimates * Zoom Video Drops 8% After Salesforce Sells Off Stake * J2 Global Surges 15% On Earnings Beat; RBC Upgrades To ‘Buy’ * Boeing’s Aircraft Deliveries Drop In July As More 737 MAX Cancellations Hit
- The Telegraph
Airbnb is planning to file for a US float in the coming weeks, putting the short-term rental company on course to go public by the end of this year. The company expects to file confidentially for an initial public offering as soon as this month, The Telegraph understands. The company could be worth more than $30bn (£23bn) after emerging from the pandemic-induced travel slump stronger than many had expected. Airbnb, which lets landlords rent out rooms or properties and takes a portion of each booking, was preparing to file paperwork in New York in early 2020. It was forced to freeze plans as the coronavirus spread, resulting in an economic downturn coupled with stay-at-home orders and travel bans that caused bookings to crater. The company laid off a quarter of its workforce and took new funding at a hefty cut to its valuation to shore up cash. But growing demand for countryside escapes has led bookings to recover in many places, while workers barred from the office have turned to the site to book stays of several weeks outside of cities. Airbnb had been considering a “direct listing”, in which a company floats on a stock exchange without issuing new shares, but buoyant stock market conditions and its larger debt pile means it is now more likely to raise money. Companies including Spotify and Slack have carried out direct listings in recent years. Going public this year will present a windfall for Airbnb’s employees, presenting a route for them to cash stock options that begin to expire in November, becoming worthless. Uncertainty caused by the US election or a drop in market conditions could still force it to delay plans, however. The company is one of the highest-valued privately-held US tech companies, and staff had been pushing for it to list on the stock market. Data company Palantir and takeaway app DoorDash are among others working on a float. Airbnb’s plans to file to go public were first reported by the Wall Street Journal.
Target (TGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500's (NYSE: SPY) total return for the decade was 250.5%. But there's no question some big-name stocks did much better than others along the way.Sony's Difficult Decade: One underperformer of the last decade was Japanese electronics and media giant Sony Corp (NYSE: SNE).One of the biggest changes for Sony in the past decade was Kazuo Hirai taking over as president and CEO in 2012. After years of losses, Hirai said he planned to focus Sony's electronics business on three areas: imaging technology, gaming and mobile technology. At the same time, he wanted to focus on reducing losses in the company's TV business.Throughout the decade, Sony trimmed non-core businesses, including selling off its Vaio PC division in 2012 and divesting its lithium-ion battery business in 2017. Sony also fully acquired its Sony Financial Holdings subsidiary in 2019.Sony shares started the 2010s trading at around $30. After peaking at $40.45 in early 2010, the stock began to tank in early 2011, ultimately hitting its decade low of $9.57 in late 2012. After the CEO change was announced, Sony shares began to gain steam, ultimately making new highs above $40 by the end of 2017.Sony hit the $60 mark in 2018 and the $70 mark in early 2020.While sales growth from the company's gaming segment slowed in recent years due to an aging PlayStation 4, Sony's image sensor business is booming. Sony currently supplies image sensors for roughly half of the world's smartphone makers. In addition, the stock hit new highs in 2020 as investors anticipate a major revenue boost from the launch of the PlayStation 5 ahead of the holiday season.2020 And Beyond: Sony recently peaked at $84.14 after dropping down to just $50.94 during the COVID-19 sell-off in March. While the stock has been a top market performer since late 2012, its horrendous performance in 2011 and 2012 have weighed on its overall 10-year returns.In fact, $1,000 worth of Sony stock in 2010 would be worth about $2,806 today, assuming reinvested dividends.Looking ahead, analysts expect Sony's climb to continue in the coming months. The average price target among the 22 analysts covering the stock is $91.56, suggesting 15.1% upside from current levels.See more from Benzinga * This Day In Market History: Microsoft's First Software Deal(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- PR Newswire
Hightower today announced it has made a strategic investment in Teak Tree Capital Management, a $600 million advisory business in Fort Worth, Texas, that specializes in financial planning and research-driven investment strategies designed to protect and grow wealth.
More From Yahoo Finance Video
- Yahoo Finance Video
Galileo Russell, HyperChange Founder, joined The Final Round to discuss Tesla announcing a five-for-one stock split and how the company stacks up to its competition.
- Yahoo Finance Video
On Wednesday, Deutsche Bank initiated coverage of Roku with a buy and $185 price target, noting that Roku is the market leader in the connected TV (CTV) market. Looking ahead, the firm believes ad-supported TV and The Roku Channel are key to Rroku’s business model. The Final Round panel discusses the bullish call.
- Yahoo Finance Video
Christian Magoon, CEO of Amplify ETFs, joins Yahoo Finance's Kristin Myers to discuss the growing consumer interest in performing transactions online as many Americans stay at home during the pandemic.
- Yahoo Finance Video
As a result of the pandemic, many investors expect a continued economic contraction in the short term, and ongoing pain in the intermediate term until a vaccine is widely available. Hennessy Focus Fund Co-Portfolio Manager David Rainey joins The Final Round panel to break down why long-term GDP and corporate profits are at as much of a risk as initially thought.